Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

Wednesday saw a full slate of clinical updates across the globe for vaccine and therapeutic candidates to address COVID-19, while HHS launched a new public-private partnership to ramp up emergency drug packaging capabilities.

Roivant Sciences GmbH said it has engaged U.S., European and Asian regulators to enable clinical testing of gimsilumab to prevent and treat acute respiratory distress syndrome (ARDS), which is caused by lung tissue damage and inflammation, in COVID-19 patients. To date, the only treatment for ARDS is mechanical ventilation...